Recall Alert
PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES
DRAP Alert No | No I/S/09-25-75 |
Action Date | 19th September, 2025. |
Target Audience | – National Regulatory Field Force. – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public |
Problem / Issue | Drug Testing Laboratory Faisalabad has informed the Drug Regulatory Authority of Pakistan that the samples of below mentioned drug product has been declared as ‘Substandard’. |
Therapeutic Goods (s) Affected: –
S# | Product Name | Batch No. | Manufacturers | Remarks |
1. | Wisdom powder for injection (Ceftriaxone 500mg) | WSM-027 | Trigon Pharmaceuticals (Pvt.) Ltd., Thokar-Raiwind road, Lahore. | Substandard on the basis of failure of sterility test. |
Risk Statement: | Use of the affected batches of Ceftriaxone Injection may pose a significant risk to patient safety. As this product is administered parenterally, compromised quality (such as sterility failure) can result in serious adverse health consequences. Potential risks include treatment failure, severe infection, sepsis, or life-threatening hypersensitivity reactions. Vulnerable populations, including neonates, children, and immunocompromised patients, are at particular risk of harm. Therefore, continued distribution or use of the defective product may lead to serious, sometimes fatal, health outcomes. |
Action Initiated | – The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined and returned to the supplier/company. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms∂dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s). |
Advice for Healthcare Professionals | DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP. |
Advice for Consumers | -Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist. |